Real-world clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen vs insulin detemir disposable pen in a US managed care setting

Abstract

INTRODUCTION • The supplementation of oral antidiabetic drugs (OADs) with basal analog insulins, such as insulin glargine or insulin detemir, can provide clinically important improvements in glycemic control, with low hypoglycemic rates.1 • Insulin glargine and insulin detemir can be administered using disposable pen devices and evidence suggests that pen devices may be easier, less painful, and preferred by patients, compared with vials and syringes. As a result, it is thought that pen devices may improve adherence and help overcome the barriers to insulin use. • Few studies have compared real-world outcomes following initiation of different analog insulin pen regimens; such information would assist with treatment decisions and help optimize the management of patients with type 2 diabetes mellitus (T2DM).